Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws

IF 0.2 4区生物学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Law Report Pub Date : 2023-10-01 DOI:10.1089/blr.2023.29320.cmh

CHRISTOPHER M. HOLMAN

{"title":"Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws","authors":"CHRISTOPHER M. HOLMAN","doi":"10.1089/blr.2023.29320.cmh","DOIUrl":null,"url":null,"abstract":"Biotechnology Law ReportAhead of Print Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent LawsBy CHRISTOPHER M. HOLMANBy CHRISTOPHER M. HOLMANChristopher M. Holman is a Professor of Law at the University of Missouri-Kansas City School of Law; a Senior Scholar at the Center for Intellectual Property x Innovation Policy (C-IP) at George Mason University, Antonin Scalia Law School; and the Executive Editor of Biotechnology Law Report.Search for more papers by this authorPublished Online:25 Sep 2023https://doi.org/10.1089/blr.2023.29320.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 0Issue 0 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:By CHRISTOPHER M. HOLMAN.Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws.Biotechnology Law Report.ahead of printhttp://doi.org/10.1089/blr.2023.29320.cmhOnline Ahead of Print:September 25, 2023PDF download","PeriodicalId":55354,"journal":{"name":"Biotechnology Law Report","volume":"62 1","pages":"0"},"PeriodicalIF":0.2000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Law Report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/blr.2023.29320.cmh","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Biotechnology Law ReportAhead of Print Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent LawsBy CHRISTOPHER M. HOLMANBy CHRISTOPHER M. HOLMANChristopher M. Holman is a Professor of Law at the University of Missouri-Kansas City School of Law; a Senior Scholar at the Center for Intellectual Property x Innovation Policy (C-IP) at George Mason University, Antonin Scalia Law School; and the Executive Editor of Biotechnology Law Report.Search for more papers by this authorPublished Online:25 Sep 2023https://doi.org/10.1089/blr.2023.29320.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 0Issue 0 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:By CHRISTOPHER M. HOLMAN.Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws.Biotechnology Law Report.ahead of printhttp://doi.org/10.1089/blr.2023.29320.cmhOnline Ahead of Print:September 25, 2023PDF download

查看原文本刊更多论文

联邦巡回法院重申药物安全和有效性是FDA的问题，而不是专利法的问题

联邦巡回法院重申药物安全和有效性是FDA的问题，而不是专利法CHRISTOPHER M. Holman CHRISTOPHER M. Holman是密苏里大学堪萨斯城法学院的法学教授;乔治梅森大学安东宁·斯卡利亚法学院知识产权与创新政策中心(C-IP)高级学者;也是《生物技术法律报告》的执行主编。搜索本文作者的更多论文出版在线:2023年9月25日https://doi.org/10.1089/blr.2023.29320.cmhAboutSectionsView文章查看全文pdf /EPUB权限和引文下载CitationsTrack引文添加到收藏回到出版物共享在facebook上分享推特链接在redditemail查看文章figuresreferencesrelateddetails卷0发行0信息版权2023,Mary Ann Liebert, Inc.，出版商引用本文:by CHRISTOPHER M. HOLMAN。联邦巡回法院重申药物安全和有效性是FDA的问题，而不是专利法的问题。生物技术法律报告。打印前://doi.org/10.1089/blr.2023.29320.cmhOnline打印前:2023年9月25日pdf下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Law Report 工程技术-生物工程与应用微生物

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The leading authoritative journal since 1982 devoted to the evolving body of law and government regulation concerning biotechnology, particularly in the industries in which new products from these technologies are developing the most rapidly: pharmaceuticals, chemicals, agriculture, food processing, energy, mineral recovery, and waste treatment. All legal aspects are rapidly reported, and critical and often hard-to-obtain documents are reproduced.